Development and Implementation of a Comprehensive Initiative to Educate Healthcare Providers and Patients in the United States about the Risk of Drug-Drug Interactions Associated with Nirmatrelvir/ritonavir during the COVID-19 Pandemic

This case study describes the development of a comprehensive drug-drug interaction (DDI) education initiative for nirmatrelvir/ritonavir (Paxlovid™) during the COVID-19 pandemic. Following Emergency Use Authorization in December of 2021, the rapid dissemination of information on identification and management of DDIs was needed to ensure appropriate use of nirmatrelvir/ritonavir when treating patients with COVID-19 who were at an increased risk of progression to severe illness. The initiative included comprehensive outreach activities to compliantly inform healthcare providers and patients through the development of various educational materials and omnichannel engagement strategies. This case study may serve as an example to guide best practices for therapeutics requiring timely and comprehensive approaches to the dissemination of medical information in the future.